Similar to IDH1 mutation, 5hmC can be a proper biomarker for distinguishing patients with GBM from gliomas, indicating the potential utility of 5hmC in gliomas screening (Cai et al., 2021). This evidence concerns the gene IDH1 and glioblastoma.